Inc-REG3G-3-1/miR-215-3p Promotes Brain Metastasis of Lung Adenocarcinoma by Regulating Leptin and SLC2A5

Chunyang Jiang 1*, Hui Zhao 1†, Bingjun Yang 1†, Zengfeng Sun 2, Xin Li 3 and Xiaoli Hu 4

1 Department of Thoracic Surgery, Tianjin Union Medical Center, Nankai University, Tianjin, China, 2 Key Laboratory of Cancer Prevention and Therapy, Department of Neurosurgery and Neurooncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, 3 Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, China, 4 Department of Respiratory, The Second People’s Hospital of Linhai City, Taizhou, China

This study aims to explore the role and mechanism of specific IncRNA in brain metastasis (BM) from lung adenocarcinoma (LADC), providing an effective biomarker for early diagnosis and targeted therapy of BM from LADC. Based on the gene expression profiles of IncRNA and mRNA in LADC and BM tissues detected by Gene Chip, Inc-REG3G-3-1 was selected, and the related genes, including miR-215-3p, leptin, and SLC2A5, were identified by data analysis. Human LADC cell lines A549 and H1299 were cultured. Dual-luciferase and endogenous validation experiments were used to confirm the regulation between these genes. Real-time quantitative reverse transcription–polymerase chain reaction and Western blotting were used to detect gene expression. The tumor metastasis-related gene function of lnc-REG3G-3-1 and miR-215-3p in H1299 cells was verified by Transwell invasion, migration assays, and scratch testing. Nude mice xenograft tumors constructed with decreased lnc-REG3G-3-1 confirmed the influences on gene expression in vivo. Inc-REG3G-3-1 was highly expressed in BM tissues that originated from LADC compared with that in primary cancer tissues. Inc-REG3G-3-1 reduced miR-215-3p expression, thereby regulating the target genes leptin and SLC2A5 and the signaling pathways, taking part in the lnc-REG3G-3-1/miR-215-3p axis in the process of BM from LADC. Inc-REG3G-3-1, leptin, and SLC2A5 through regulating signaling pathways may be jointly involved in the regulation of the biological process of BM in patients with LADC.

Keywords: IncRNA, microRNA, lung adenocarcinoma, brain, metastases

INTRODUCTION

The morbidity and mortality of lung cancer are highest among malignant tumors in some large cities of industrialized countries (1, 2). Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer (3), and adenocarcinoma is the most common histological type, accounting for about 35% of lung cancer cases, which is more prone to blood and lymphatic metastasis (4). Metastasis is a malignant sign and characteristic of lung cancer and also a major cause of treatment failure and patient death (5). The early diagnosis of lung cancer metastasis is very important for improving the treatment level and prognosis of patients.
Although current studies have found that multiple mechanisms are involved in the metastasis process of lung cancer (6–9), the molecular mechanism of lung cancer metastasis is still not completely clear. Therefore, elucidating the molecular mechanism of lung cancer metastasis can better understand the complex biological behavior of lung cancer and search for molecular markers or targets that are sensitive to the early diagnosis and treatment of lung cancer metastasis to provide a scientific basis for preventing or delaying the occurrence and development of metastasis and effectively improving the prognosis of patients.

The high incidence of brain metastases (BMs) in lung adenocarcinoma (LADC) often lacks effective treatment. It is an important cause of treatment failure and patient death (10). Patients with BMs experience poor prognosis and significant morbidity, often with a median survival time of 3–6 months (11). The process of BMs from LADC in specific mechanism studies is not enough. The lack of an effective early diagnosis method of BMs from LADC results in some patients already with distant metastasis when seeing a doctor or in the process of treatment delays the optimal timing of treatment. This would seriously influence the quality of life and long-term survival of patients with LADC.

Long non-coding RNA (lncRNA) accounts for 80% of the total amount of all non-coding RNA (ncRNA), which can regulate gene expression on multiple levels, participating in almost all physiological and pathological processes of organisms (12). The abnormal expression of lncRNA in tissues is directly related to the process of carcinogenesis. LncRNA is abnormally expressed in a variety of human tumors and shows the specificity of tumor tissue, which can regulate the biological function of specific tumor cells and is considered as a new specific tumor marker (13). More and more recent research results indicate that lncRNAs are becoming the main regulatory factors of tumor cell phenotype, involving oncogenes, and tumor suppressor genes (14). Some lncRNAs are closely related to the invasion and metastasis of malignant tumors (15). It is believed that, with the deepening of studies on the biological function of lncRNA, more lncRNAs related to tumor metastasis will be found, which will surely provide new clues for the diagnosis and treatment of tumors.

This study aims to find the specific lncRNA molecule relating BMs from LADC in situ tumor to BM tumor tissue using gene chip technology and, combined with the biological information database, through the competitive endogenous RNA (ceRNA) mechanism for microRNA (miRNA) related to specific lncRNA to verify the possible target genes and, therefore, to explore the role and mechanism of specific lncRNA in BMs from LADC. These findings provide a scientific basis for the early diagnosis and targeted therapy of BMs from LADC for application in further studies.

**MATERIALS AND METHODS**

**Main Reagents**

Human LADC cell lines A549 and H1299 and human lung normal lung epithelial cell line BEAS-2B were obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Dulbecco’s modified Eagle’s medium (DMEM), Opti-MEM, and fetal bovine serum (FBS) were obtained from Gibco (USA). The RNAPrep Pure Cell/Bacteria Kit was purchased from Tiangen Biotech (Beijing, China). Trizol reagent was purchased from Invitrogen (USA). The Revert Aid First Strand cDNA Synthesis Kit was purchased from Fermentas (Lithuania). SYBR Prime Script RT-PCR Kit and Thermal Cycler Dice™ Real Time System III were purchased from TaKaRa (Japan). Lipofectamine 2,000 was purchased from Invitrogen. The B-type plasmid small quantity rapid extraction kit was purchased from BioDev-Tech Scientific & Technical Co., Ltd. (Beijing, China). Restriction endonuclease and Trans2K Plus II DNA Marker were purchased from Fermentas (Shanghai, China). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay kit was purchased from Ameresco (Cincinnati, OH, USA). Matrigel and Transwell chambers were purchased from Becton-Dickinson Biosciences (San Jose, CA, USA).

miRNA mimics were obtained from GenePharma, Inc. (Shanghai, China). pmirGLO plasmid was constructed and obtained from Tianjin Sairbio Technology, Inc. (China). Antibodies specific to leptin, SLC2A5, JAK2, Stat3, vascular endothelial growth factor (VEGF), FLAD1, STYX1, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-JAK2 (p-JAK2) and phospho-Stat3 (p-Stat3) antibodies were purchased from Cell Signaling Technology, Inc. (USA). Goat anti-rabbit IgG coupled to horseradish peroxidase (HRP) was purchased from Pierce (Rockford, IL, USA). All other reagents used were analytical-grade laboratory chemicals from standard commercial suppliers.

**Patients and Samples**

Five paired cancer and adjacent normal tissues from five patients with lung cancer were randomly collected. All patients had surgically proven primary LADC and received pulmonary lobectomy at the Tianjin Union Medical Center (TUMC) between October 2016 and January 2017. Three paired cancer and adjacent normal tissues from three patients with BMs were randomly collected. All three patients had surgically proven BMs from LADC and received BM tumor resection at the Tianjin Medical University Cancer Institute and Hospital between October 2017 and March 2018. All samples were obtained with informed consent and underwent examination for the lncRNA expression profile of the tissues by gene chip detection. The details of the clinical and pathological information of these patients are shown in Tables 1, 2. The study was approved by the Medical Ethics Committee of the TUMC.

**Tissue Sample Gene Chip Detection**

CapitalBio Technology lncRNA + mRNA Human Gene Expression Microarray version 4.0 (CapitalBio Corp., Beijing, China) was used to detect lncRNA and mRNA expression between LADC and paracancerous tissues. The lncRNA and mRNA expression of BMs and paracancerous tissue samples of
Further analyzed by hierarchical clustering with average linkage.

Using the Adjust Data function of CLUSTER 3.0 software and subsequent enzymatic reaction. The procedure was produced by the Eberwine’s linear RNA amplification protocol. cDNA labeled with a fluorescent dye (Cy3-dCTP) was digested by a dropwise addition of 3% pepsin solution and washed with phosphate-buffered saline (PBS) twice. Slices at room temperature for 30 min. The fixed liquid was removed and washed with precooled PBS. Cells on the surface were taken out and fixed with 4% paraformaldehyde for 2% and 0.5% CO2. The liquid was removed and washed with phosphate-buffered saline (PBS). Cells were dehydrated and dried in air. Each well was added with 300 μL of 4,6-diamidino-2-phenylindole (1 μg/mL) for 5 min. The liquid was removed and washed with precooled PBS. Cells on the glass slices were observed and photographed under a fluorescence microscope.

**Real-Time Quantitative Reverse Transcription–Polymerase Chain Reaction (RT-PCR)**

After cell collection, total cellular RNA was isolated. A total of 2.0 μg RNA was reverse transcribed to cDNA using Revert Aid First Strand cDNA Synthesis Kit. All primers were designed and synthesized by the General Biosystems, Inc. (Anhui, China). For primer sequences for miRNAs, Inc-REG3G-3-1, leptin, SLC2A5, and β-actin, see **Supplementary Table 1**; for primer sequences for Inc-REG3G-3-1-3'-UTR-wt and Inc-REG3G-3-1-3'-UTR-mut, see **Supplementary Table 2**; for primer sequences for shR-Inc-REG3G-3-1, see **Supplementary Table 3** and for primer sequences for Stat3, mammalian target of rapamycin (mTOR), JAK2, STYXL1, VEGF, AKT, Notch-1, phosphatidylinositol 3-kinase (PI3K), CUL7, FLAD1, and SOX4, see **Supplementary Table 4**. Real-time RT-PCR was used with the SYBR Premix Ex Taq kit and detected with Thermal Cycler Dice™ Real-Time System III. The housekeeping gene was validated by agarose gel electrophoresis and β-actin was selected and used as an internal control in parallel for each trial. The fluorescence threshold value was calculated using SDS 2.2.1 system software, and the 2-ΔΔCt method was applied for quantitative calculation. All experiments were performed three times independently, and the average was used for comparison.

**RNA Fluorescence in situ Hybridization (FISH)**

H1299 cells (1 × 10^5) were inoculated in 24-well cell culture plates (with a glass slice at the bottom) and placed in an incubator at 37°C, 5% CO2 for 24 h. The glass slices with cell growth on the surface were taken out and fixed with 4% paraformaldehyde at room temperature for 30 min. The fixed liquid was removed and washed with phosphate-buffered saline (PBS) twice. Slices were digested by a dropwise addition of 3% pepsin solution (1 mL) and blended for 2 min at 37°C. Cells were washed, and prehybridization solution (20 μL) was added and incubated. After hybridization, SSC buffer was used to wash the cells. Cells were dehydrated and dried in air. Each well was added with 300 μL of 4,6-diamidino-2-phenylindole (1 μg/mL) for 5 min. The liquid was removed and washed with precooled PBS. Cells on the glass slices were observed and photographed under a fluorescence microscope.

**Target Gene Verified by Dual-Luciferase Method**

After H1299 cells were transfected, dual-luciferase reporter gene assay was performed according to the kit. The report gene

---

**TABLE 1 | Clinical characteristics of patients with lung adenocarcinoma (n = 5).**

| Clinical factors          | Data            |
|--------------------------|-----------------|
| Age (years)              | 65.4 (mean)     |
| Gender (Male/Female)     | 2/3             |
| Smoking (Y/N)            | 2/3             |
| Single or multiple       | S               |
| Tumor diameter (cm)      | 3.42 (mean)     |
| Histology                | LADC            |

**TABLE 2 | Clinical characteristics of patients with lung adenocarcinoma and brain metastases of lung adenocarcinoma (n = 3).**

| Clinical factors        | No 1 | No 2 | No 3 |
|-------------------------|------|------|------|
| Age (years)             | 61   | 52   | 58   |
| Gender                  | F    | F    | M    |
| Smoking                 | N    | N    | N    |
| Tumor site in brain     | Cerebellum | Occipital lobe/parietal lobe | Occipital lobe |
| Single or multiple      | Multiple | Two sites | Single |
| Tumor volume (cm)       | 4.0 × 3.0 cm | 4.0 × 3.2 cm/5.2 × 3.4 cm | 5.0 × 4.0 cm |
| Histology               | Adenocarcinoma | Adenocarcinoma | Adenocarcinoma |

LADC were also detected using this. The test method number was AG-GE-WL10-01-2010, and the data analysis method number was AG-GE-DL00-01-2010.
cell lysis fluid was used as a blank control. After completing the determination of firefly luciferase, 100 μL Renilla luciferase assay solution was added and homogenized, and RLU was determined by GloMax 96 microporous plate luminescence detector. The internal reference was Renilla luciferase. The RLU value determined by firefly luciferase was divided by the RLU value determined by Renilla luciferase. The degree of gene activation was compared between different samples according to the ratio obtained.

**Cell Transfection**
The H1299 cell suspension was drained, and 1 × 10^5 cells were inoculated in a six-well cell culture plate in an incubator at 37°C, 5% CO₂ for 24 h. Cell transfection solutions A and B were prepared in a sterilized 1.5 mL centrifuge tube. Liquid A was obtained by diluting 6 μL transfection reagent with serum-free DMEM to a final volume of 50 μL. Liquid B was obtained by diluting 3 μL Lipofectamine 2,000 reagent with serum-free DMEM to a final volume of 50 μL. Solutions A and B were gently mixed and placed at room temperature for 5 min. The mixing transfection solution and Opti-MEM were added to each well of the cell culture plate, and the transfected cells were cultured in an incubator at 37°C, 5% CO₂.

**Western Blotting and MTT Assay**
Western blotting and MTT assay were performed as described in our previous studies (18, 19).

**Transwell Invasion and Migration Experiments**
Each Transwell chamber was coated with 10 μL fibronectin (0.5 mg/mL) and dried to solidify fibronectin at the bottom of the membrane. Dissolved matrix glue was added at 50 μL/well. At the same time, transfected H1299 cells were digested and counted. Then, 10^5 cells were placed into a 1.5 mL EP tube and centrifuged at 2,000 rpm for 5 min, the supernatant was removed, and the suspended cells were added into the Transwell chamber with 200 μL serum-free DMEM. DMEM containing 20% serum (Gibco) was added to the lower chamber. Cells were incubated at 37°C for 24 h. The Transwell chamber was removed, and the cells were gently washed with PBS. The mixed solution was prepared with methanol/glacial acetic acid (3:1), and the cells on the opposite side of the Transwell chamber were fixed for 30 min and then added into crystal violet dye solution, stained for 15 min, and cleaned. The membrane was fixed on the glass slide for observation.

**Scratch Test**
The ability of cell migration was measured by the scratch test. The transfected H1299 cells were cultured in a 24-well plate until the density was close to the fusion state. The tip of the add sampler was used against the ruler as perpendicular as possible to the horizontal line behind the plates to perform the scratch test. The cells were washed with PBS three times to remove the subtracted cells, and serum-free medium was added. The cells were added to the culture plate in an incubator at 37°C, 5% CO₂. Samples were taken at 0, 24, and 48 h, and photos were taken under the microscope.

**Xenograft Tumors in Nude Mice**
Female BALB/c nude mice (8 weeks old) were purchased from the Experimental Animal Center of the Chinese Academy of Sciences. The experimental protocols were approved by the ethics committee of TUMC. The animals were divided into three groups: blank H1299 control group, pSilencer-NC group, and pshR-REG3G-3-1 group, with six nude mice in each group. The screened stable H1299-pSilencer-NC and H1299-pshR-REG3G-3-1 cells were amplified and cultured, respectively. Then, a 1-mL syringe was used to absorb the cell suspension by emptying bubbles and injected subcutaneously into the right back of nude mice. The control group was injected with H1299 cells. The transfection control group was injected with tumor cells H1299-pSilencer-NC. The transfection group was injected with tumor cells H1299-pshR-REG3G-3-1. The weight of nude mice was measured before inoculation, and the tumor could be felt under the skin (~12 days). The body weight of each animal was weighed every 5 days. Tumor length and short diameters were measured every 3 days to calculate the tumor volume. The average tumor volume of each group was used to plot the growth curve of the transplanted tumors. After 22 days, nude mice were euthanized with ether anesthesia and photographed. The tumor was completely removed, weighed, and photographed (with scale). The tumor samples were divided into two parts: one was fresh tumor tissue stored at −80°C for the detection of gene and protein expression, and the other was placed in neutral formalin for fixation for immunohistochemical examination as described previously (20).

**Statistical Analysis**
All data were analyzed using two-way univariate analysis of variance followed by Tukey’s (equal variances assumed or homogeneity of variance after variable transformation) or Dunnett’s T3 (equal variances not assumed after variable transformation justification) post-hoc test between groups using the Statistical Package for Social Sciences software version 20.0 (SPSS, Chicago, IL, USA). Results were taken as mean ± SD. All tests were two sided. P < 0.05 was considered statistically significant.

**RESULTS**

**Differential Expression of IncRNAs and mRNAs in Cancer Tissues**
By detecting the gene expression profiles of IncRNA and mRNA in cancer tissues of five cases of LADC and the paired paracancerous tissue samples, it was found that there were a large number of differentially expressed IncRNAs and mRNAs in LADC tissues and paracancerous tissues. The expression differences of IncRNA and mRNA are listed in Supplementary Table 5 [total 20,179, shown are FC (abs) more than 2.0 times] for LADC IncRNA and Supplementary Table 6 [total 25,154, shown are FC (abs) more than 2.0 times] for LADC...
FIGURE 1 | Cellular functions of Inc-REG3G-3-1 and miR-215-3p in H1299 cells. After transfection with plasmids, the expression of Inc-REG3G-3-1 and miR-215-3p were regulated. After cells were cultured for 24, 48, and 72 h, MTT assay was used to detect H1299 cell viability (A, a, b). After transfection with plasmids to regulate the expression of Inc-REG3G-3-1 and miR-215-3p for 24 h, Transwell invasion and Transwell migration assays were used to detect the differences of migration and (Continued)
mRNA. The detection results of the expression profiles of gene groups in heat maps are shown in Supplementary Figure 1A.

By detecting the gene expression profiles of IncRNA and mRNA in three cases of BMs from LADC and matched paracancerous tissues, it was found that there were significant differences in the expression of IncRNAs and mRNAs between BM tumors of LADC and paracancerous tissues. The differences between IncRNA and mRNA expression are listed in Supplementary Table 7 for IncRNA and Supplementary Table 8 for mRNA. The genetic heat maps of the test results are shown in Supplementary Figure 1B. All these data are provided by CapitalBio for detection and analysis.

**Combined Enrichment Gene Microarray in Tissues of LADC and BM Tumors From LADC**

In order to find whether there exist key genes related with LADC and BMs, the combined analysis of the IncRNA expression difference between BMs and LADC tissues (T vs. C) of these patients were performed, and the results are listed in Supplementary Table 9 [total 26,642, shown are FC (abs) more than 2.0 times]. According to the relationship between IncRNAs and signaling pathway genes, the enrichment analysis results of the signal transduction pathway involving the first 10 IncRNAs in P-value sequencing showed that the IncRNAs related to NSCLC presented significant enrichment (Supplementary Figure 2). The significant differences in IncRNA expression (top 8) between LADC and BMs from LADC are listed in Supplementary Table 10. Two IncRNAs were significantly upregulated, including ENST00000439259.1 (Inc-REG3G-3-1), and six IncRNAs were significantly downregulated. For the two upregulated IncRNAs, the shorter Inc-REG3G-3-1 was first selected to performed confirmatory study. The RNA-protein interaction prediction (RPISeq) database was used to analyze and predict the interaction between Inc-REG3G-3-1 and target genes. The results showed that the RF classifier and SVM classifier values of Inc-REG3G-3-1 and leptin and SLC2A5 were <0.5 (0.83, 0.89; 0.75, 0.81, respectively), indicating a strong interaction relationship. Standalone BLAT v.35 was used to predict Inc-REG3G-3-1 and target mRNAs, and the results showed that Inc-REG3G-3-1 could regulate the expression of target genes leptin and SLC2A5.

**Effect of Inc-REG3G-3-1 and miR-215-3p on Cellular Functions**

The MTT assay was used to detect the viability of H1299 cells. The results showed that, at 48 and 72 h, overexpressed Inc-REG3G-3-1 can significantly increase H1299 cell viability compared with the control group. After the knockdown of Inc-REG3G-3-1, the cell activity was significantly lower than that of the control group (Figure 1A,a). When miR-215-3p was overexpressed and cultured for 48 and 72 h, cell viability was significantly decreased compared with that of the control group, whereas with the knockdown of miR-215-3p and culture for 48 and 72 h, cell viability was significantly increased compared with the control group (Figure 1A,b).

The transwell invasion and migration assays combined with the scratch test were employed to detect the changes in the ability of cells to invade and migrate induced by regulation of Inc-REG3G-3-1 or miR-215-3p expression. The results showed that, compared with the control group, the overexpression of Inc-REG3G-3-1 can significantly enhance the migration and invasion abilities of cells, whereas the knockdown of Inc-REG3G-3-1 can significantly reduce the migration and invasion abilities of cells (Figures 1B–D). In contrast, the overexpression of miR-215-3p significantly reduced the abilities of cell migration and invasion compared with the control group. However, the knockdown of miR-215-3p significantly increased the migration and invasion abilities of cells compared with the control group (Figures 1B,C,E).

**Expression Differences of Inc-REG3G-3-1, Leptin, and SLC2A5 Genes and miRNAs**

Based on these bioinformatics results, real-time RT-PCR was used to detect the expression differences of Inc-REG3G-3-1, leptin, and SLC2A5 genes and the three miRNAs in A549 and H1299 cells and human normal lung epithelial cell line BEAS-2B as control. The results show that the expression of Inc-REG3G-3-1, leptin, and SLC2A5 in A549 and H1299 cells was significantly increased compared with that in control cells, and the expression in H1299 cells was significantly increased compared with that in A549 cells (Figure 2A). The expression of miR-215-3p was significantly decreased in both A549 and H1299 cells, and the expression of miR-5787 was significantly increased. miR-4505 was decreased in A549 cells and increased in H1299 cells (Figure 2B).

**Expression and Localization of Inc-REG3G-3-1 in H1299 Cells**

The subcellular localization of IncRNA is closely related to its mechanism of action. The RNA FISH assay is an important method for IncRNA subcellular localization, which was employed in the present study to detect the expression and localization of Inc-REG3G-3-1 in H1299 cells. H1299 cells were transfected with the FITC probe, which was constructed and labeled by Inc-REG3G-3-1 FISH to observe the relative localization and expression of Inc-REG3G-3-1 in H1299 cells. The results showed...
FIGURE 2 | Differential expression of Inc-REG3G-3-1, miR-215-3p, leptin, and SLC2A5 and miRNAs in lung cancer cell lines and cellular localization of Inc-REG3G-3-1. Real-time RT-PCR was employed to confirm the expression differences of the gene levels of Inc-REG3G-3-1, leptin, and SLC2A5, and three miRNAs, including miR-215-3p, miR-5787, and miR-4505 in A549 and H1299 cells and the BEAS-2B cell line as control. The results are shown in (A,B). RNA FISH assay was (Continued)
that Inc-REG3G-3-1 had abundant expression in the cytoplasm (Figure 2C).

**Confirmation of miR-215-3p as a Specific Adsorption Target Gene of Inc-REG3G-3-1**

Luciferase reporter gene assays using luciferin as the substrate to detect the activity of firefly luciferase are widely used for miRNA target gene validation. In the present study, dual-luciferase reporter assay was used to verify whether Inc-REG3G-3-1 has a specific adsorption effect on miR-215-3p in H1299 cells. The results show that luciferase activity decreased after the overexpression of miR-215-3p and increased after the knockdown of miR-215-3p. After mutation of Inc-REG3G-3-1, miR-215-3p did not affect luciferase activity. The results confirm that Inc-REG3G-3-1 had a specific adsorption effect on miR-215-3p (Figure 2D).

**Endogenous Verification That Inc-REG3G-3-1 Affected the Expression of miR-215-3p, Leptin, and SLC2A5**

By transfecing the recombinant plasmid pcDNA3.1/Inc-REG3G-3-1 and pshR-Inc-REG3G-3-1, the effects of the overexpression and knockdown of Inc-REG3G-3-1 on the expression levels of miR-215-3p, leptin, and SLC2A5 in H1299 cells were detected by real-time RT-PCR. The results show that the overexpression of Inc-REG3G-3-1 inhibited the expression of miR-215-3p, and the knockdown promoted its expression, further verifying the targeted adsorption effect of Inc-REG3G-3-1 on miR-215-3p. The overexpression of Inc-REG3G-3-1 promoted the expression of leptin and inhibited the expression of leptin after knockdown. The overexpression of Inc-REG3G-3-1 promoted the expression of SLC2A5 and inhibited its expression after knockdown (see Figure 2E).

**Verification of the Targeting Effects of miR-215-3p on Leptin and SLC2A5**

The dual-luciferase reporter assay results show that, when miR-215-3p was overexpressed, luciferase activity decreased, whereas the knockdown of miR-215-3p increased luciferase activity. After leptin-3' UTR mutation, the changes in miR-215-3p did not affect the activity of luciferase. The results show that miR-215-3p has a targeting effect on leptin (Figure 2F,a). After SLC2A5-3' UTR mutation, the changes in miR-215-3p did not affect the activity of luciferase. The results show that miR-215-3p has a targeting effect on SLC2A5 (Figure 2F,b).

**Effect of miR-215-3p on mRNA Expression of Genes Related to Leptin and SLC2A5 Signaling Pathway**

Genes including Stat3, mTOR, JAK2, VEGF, AKT, Notch-1, and PI3K are tightly related with leptin expression and as key genes in the signal transduction. STYXL1, CUL7, FLAD1, and SOX4 are important functional genes associated with the SLC2A5 signaling pathway. After the overexpression or knockdown of miR-215-3p, the mRNA expression levels of leptin, SLC2A5, Stat3, mTOR, JAK2, VEGF, AKT, Notch-1, PI3K, STYXL1, CUL7, FLAD1, and SOX4 were detected by real-time RT-PCR. The results show that the overexpression of miR-215-3p significantly inhibited the mRNA expression of leptin and SLC2A5, and the mRNA expression of VEGF, Notch-1, STYXL1, and FLAD1 was also significantly decreased, whereas the expression of AKT, PI3K, and SOX4 was significantly increased. After the knockdown of miR-215-3p, the mRNA expression of leptin and SLC2A5 was significantly enhanced, and the mRNA expression of VEGF, Notch-1, STYXL1, and FLAD1 was also significantly enhanced, whereas the mRNA expression of AKT, PI3K, and SOX4 was significantly decreased. The expression regulation of miR-215-3p had no effect on the mRNA expression levels of Stat3, mTOR, JAK2, and CUL7. In spite of this, these results could confirm the endogenous targeted regulatory effect of miR-215-3p on leptin and SLC2A5 and affect the mRNA expression level of some related signaling pathway molecules of these two genes (Figure 3A).

**Effect of miR-215-3p on Protein Expression of Genes Related to Leptin and SLC2A5 Signaling Pathway**

After the overexpression or knockdown of miR-215-3p, the protein expression levels of leptin, SLC2A5, Stat3, p-Stat3, JAK2, p-JAK2, VEGF, STYXL1, and FLAD1 were detected by Western blotting. The results showed that the overexpression of miR-215-3p significantly decreased the protein expression of leptin, SLC2A5, p-Stat3, p-JAK2, VEGF, STYXL1, and FLAD1, whereas, with the knockdown of miR-215-3p, these proteins levels were markedly elevated. However, the overexpression or knockdown of miR-215-3p has not induced differences in the protein expression levels of Stat3 and JAK2. The results are shown in Figures 3B,C.

**Reduction of Inc-REG3G-3-1 Changed the Growth of Xenograft Tumors in Nude Mice**

The results of the changes in body weight and the growth curve of the transplanted tumors showed that downregulated Inc-REG3G-3-1 remarkably inhibited the growth of the transplanted
FIGURE 3 | miR-215-3p effect on mRNA and protein expression of genes related to leptin and SLC2A5 signaling pathway. After the overexpression or knockdown of miR-215-3p by transfected plasmids, the mRNA expression levels of leptin, SLC2A5, Stat3, mTOR, JAK2, VEGF, AKT, Notch-1, P38, STYXL1, CUL7, FLAD1, and SOX4 were detected by real-time RT-PCR (A). Upregulation or downregulation of miR-215-3p by transfected plasmids and the protein expression levels of leptin, (Continued)
FIGURE 3 | SLC2A5, Stat3, p-Stat3, JAK2, p-JAK2, VEGF, STYXL1, and FLAD1 were detected by Western blotting (B) and were analyzed the expression differences (C). GAPDH was used as a loading control. Representative blots were shown and repeated three times. Bar graphs represent the analysis of the ratios of each protein expression band density to that of GAPDH for nine genes. The ratios were plotted as mean ± SD of three separate experiments. Compared with the control group, “ns” means no statistical difference between means, *P < 0.05; **P < 0.01; ***P < 0.001.

FIGURE 4 | Reduction of lnc-REG3G-3-1 changed the growth of xenograft tumors in nude mice and gene expression levels. The average body weight and tumor volume of each group were obtained during modal mice feeding. The changes in body weight and the growth curve of the tumors are shown in (A,B). The dots of line charts represent the numbers plotted as mean ± SD (n = 6). After 21 days, the subcutaneous tumors were removed from each mouse separately (C). After modeling of nude mice xenograft tumors, the subcutaneous tumors were removed and the gene expression of lnc-REG3G-3-1 and miR-215-3p was detected by real-time RT-PCR (D). Western blotting (E,F) and immunohistochemistry (G) were used to detect the protein levels of leptin and SLC2A5 in tumor tissues. GAPDH was used as loading control. Bar graphs represent the analysis of the ratios of each target band density to that of GAPDH in each group for three genes in tumor tissues. The ratios were plotted as mean ± SD of three separate experiments. Compared with the control group, *P < 0.05; **P < 0.01; ***P < 0.001. For immunohistochemical results, representative photos are shown. Brown staining showed strong protein expression, whereas pale blue staining showed weak protein expression.

Reduction of Inc-REG3G-3-1 Changed the Gene Expression Levels in Tissues of Xenograft Tumors in Nude Mice

At the end of feeding and completion of xenograft tumors in nude mice, the subcutaneous tumors were removed. Real-time RT-PCR was employed to detect the gene expression of Inc-REG3G-3-1 and miR-215-3p. The results showed that, compared with the control group, the Inc-REG3G-3-1 in the knockdown group was significantly decreased in tumor tissues, whereas the miR-215-3p level was remarkably increased (Figure 4D). Western blotting and immunohistochemistry were used to detect the protein levels of leptin and SLC2A5 in tumorous tissue. The Western blotting results for leptin and SLC2A5 protein levels are shown in Figures 4E,F, whereas the immunohistochemical results are shown in Figure 4G. The results show that the reduction of Inc-REG3G-3-1 induced obviously the decrease of the protein expression of leptin and SLC2A5.

DISCUSSION

LADC is the most common pathological type of lung cancer with a high incidence of BM (21, 22). There is often a lack of effective treatment for BM from LADC with poor prognosis, and 1-year survival is 10% (23, 24). More and more evidence confirms that
lncRNAs are closely related to the invasion and metastasis of malignant tumors, including lung cancer (14, 15, 25–27). Studies have shown that the expression of specific lncRNA associated with LADC metastasis is significantly correlated with lymph node metastasis and tumor staging (28). In addition, the lncRNA expression profile in LADC may play an important role in predicting the survival of patients (29). However, the number of lncRNAs was found to be closely related to LADC metastasis is very limited, and the mechanism of function is not completely clear. Therefore, further exploration is still needed.

In this study, microarray gene chip detection found that between LADC tissue and adjacent tissue as well as BM tissues from LADC and adjacent tissue, all have differences in expression of lncRNAs and mRNAs. Therefore, miRNAs related to specific lncRNA were searched through cRNA mechanism, and their possible target genes were verified. The results show that the expression of Inc-REG3G-3-1 in BM tissues that originated from LADC was significantly higher than that in LADC tissues.

As a hormone secreted by fat cells and playing a key role in promoting angiogenesis, leptin is an important factor in the tumorigenesis, metastasis, resistance to apoptosis, and drug resistance of lung cancer and many other cancers by regulating various signal transduction pathways (30). Leptin can up-regulate the expression of VEGF when overexpressed in lung tumor tissues, thereby promoting the proliferation and remodeling of vascular endothelial cells (31). Studies have found that the P13K/protein kinase B (PKB)/mTOR signaling pathway is overactivated in NSCLC patients. Leptin activates P13K, an important molecule in the mTOR pathway, thereby activating Akt and mTOR, which are the downstream targets of P13K. The activation of this signaling pathway can regulate the expression of various tyrosine kinase receptors in lung cancer cells, promote the survival and proliferation of cancer cells, and play an important role in the invasion and metastasis of lung cancer (32). Leptin expression is significantly increased in various NSCLC cell lines, and its decreased expression level can inhibit cell proliferation and induce apoptosis through the inactivation of Notch and JAK/STAT3 signaling pathways, suggesting that downregulating leptin may be a new method to block lung cancer metastasis (32).

Fructose metabolism plays an important role in promoting the occurrence and development of malignant tumors. GLUT5, encoded by SLC2A5, is a fructose transporter unique to mammalian cells. SLC2A5 expression determines the fructose absorption and utilization efficiency of LADC cells. The overexpression of SLC2A5 can promote the proliferation, invasion, and metastasis of LADC cells. SLC2A5 may be a potential target for treating LADC alone or in combination with other therapies (33). Based on the analysis of GO, KEGG, GenMAPP, BioCarta, and disease database, the results show that reducing SLC2A5 expression can inhibit the tumorigenesis of LADC paracancerous tissues by inhibiting cell cycle–related gene CUL7 as well as STYXL1, SOX4, and FLAD1 genes (34). One study confirmed that specifically blocking the transmembrane transport of fructose can significantly inhibit the malignant proliferation, invasion, and metastasis of tumor cells in vitro (35). Reverse SLC2A5 overexpression in LADC tissues may have the biological function of inhibiting tumor metastasis of LADC, providing a possible option for the treatment of LADC.

In this study, it was found that the expression of Inc-REG3G-3-1, leptin, and SLC2A5 in A549 and H1299 cells was significantly increased compared with control cells, and the expression of miR-215-3p was significantly downregulated. These findings aroused our great interest. Experiments confirmed that Inc-REG3G-3-1 could reduce the expression level of miR-215-3p through adsorption and thereby regulate the expression levels of leptin and SLC2A5 genes. Moreover, miR-215-3p with a negative regulatory effect on leptin and SLC2A5 influenced the expression of their signaling molecules, including VEGF, Notch-1, p-Stat3, p-JAK2, STYXL1, and FLAD1. The functional results further verified that inhibiting the expression of Inc-REG3G-3-1 or increasing the expression of miR-215-3p can inhibit the tumor metastasis of LADC. Nude mice xenograft tumor experiments further confirmed that reducing Inc-REG3G-3-1 can inhibit the tumor growth by inducing increased miR-215-3p and decreasing the expression of leptin and SLC2A5 in vivo.

Collectively, the highly expressed Inc-REG3G-3-1 can reduce miR-215-3p expression and thereby regulate the expression of target genes leptin and SLC2A5. VEGF, Notch, and JAK/Stat3 signaling pathways and genes, including SOX4, STYXL1, and FLAD1 may all be related to the Inc-REG3G-3-1/miR-215-3p axis in the process of BM from LADC. Inc-REG3G-3-1/miR-215-3p, leptin, and SLC2A5 through regulating signaling pathways may be the mechanism that regulates the biological process of BM in patients with LADC.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study, these can be found in the NCBI Gene Expression Omnibus (GSE146461).

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the TUMC. The patients/participants provided their written informed consent to participate in this study. This animal study was reviewed and approved by the Medical Ethics Committee of the TUMC. Written informed consent was obtained from the owners for the participation of their animals in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

CJ, BY, and HZ conceived, designed, and carried out the experiments, analyzed the experimental data, and wrote the paper. CJ guided the experiments and prepared all figures and the table. CJ supervised and directed the project. All authors carried out the partial experiments and analyzed the experimental data. All authors discussed the results and commented on the manuscript and reviewed the manuscript.
REFERENCES

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA-Cancer J Clin. (2012) 62:10–29. doi: 10.3322/caac.20138
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA-Cancer J Clin. (2016) 66:115–32. doi: 10.3322/caac.21338
3. Longo DL, Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. (2017) 377:849–61. doi: 10.1056/NEJMra1703413
4. Kawabata S, Chang CT, Memmott RM, Komiya T, Gills JJ, Dennis PA. Rapamycin decreases expression of thymidylate synthase and enhances the response to pemetrexed in preclinical studies and a Phase I/II clinical study of subjects with non-small cell lung cancer. Cancer Res. (2014) 74:2927. doi: 10.1158/1355-7184.AM2014-2927
5. Wu T, Yin X, Zhou Y, Wang Z, Shen S, Qiu Y, et al. Roles of noncoding RNAs in metastasis of nonsmall cell lung cancer: a mini review. J Cancer Res Ther. (2015) 11(Suppl. 1):C7–10. doi: 10.4103/0973-1482.163831
6. Chiu CC, Chang HW, Chuang DW, Chang FR, Chang YC, Cheng YS, et al. Fern plant-derived protospiagenone leads to DNA damage, apoptosis, and G2/M arrest in lung cancer cell line H1299. DNA Cell Biol. (2009) 28:501–6. doi: 10.1089/dna.2009.0852
7. Wu Y, Zhou B. TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion. Br J Cancer. (2010) 102:639–44. doi: 10.1038/sj.bjc.6605530
8. Liu B, Wu X, Liu B, Wang CL, Liu Y, Zhou Q, et al. MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta. (2012) 1822:1692–704. doi: 10.1016/j.bbadis.2012.07.019
9. Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. (2016) 533:493–8. doi: 10.1038/nature18268
10. Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol. (2014) 48:173–83. doi: 10.2478/raon-2014-0014
11. Xu J, Liu X, Yang S, Zhang X, Shi Y. Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma. OncoTargets Ther. (2016) 9:2911–7. doi: 10.2147/OTT.S102472
12. Ullitsky I. Evolution to the rescue: using comparative genomics to understand long non-coding RNAs. Nat Rev Genet. (2016) 17:601–14. doi: 10.1038/nrg.2016.85
13. Nina H, Danjani G. Long non-coding RNA in cancer. Int J Mol Sci. (2013) 14:4655–69. doi: 10.3390/ijms14034655
14. Jiang C, Li X, Zhao H, Liu H. Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasis. Mol Cancer. (2016) 15:62. doi: 10.1186/s12943-016-0545-z
15. Zhuo W, Kang YB. Lnc-ing ROR1-HER3 and HIPPO signalling in metastasis. Nat Cell Biol. (2017) 19:81–3. doi: 10.1038/nclb3467
16. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, Bao W, et al. Performance comparison of one-color and two-color platforms within the microarray quality control (MAQC) project. Nat Biotechnol. (2006) 24:1140–50. doi: 10.1038/nbt1242
17. Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, et al. LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut. (2014) 63:1700–10. doi: 10.1136/gutjnl-2013-305806
18. Zhang M, Wang A, He W, He P, Xu B, Xia T, et al. Effects of fluoride on the expression of NCAM, oxidative stress, and apoptosis in primary cultured hippocampal neurons. Toxicology. (2007) 236:208–16. doi: 10.1016/j.tox.2007.04.007
19. Jiang C, Zhang S, Liu H, Guan Z, Zeng Q, Zhang C, et al. Low glucose utilization and neurodegenerative changes caused by sodium fluoride exposure in rat's developmental brain. Neuro Mol Med. (2014) 16:94–105. doi: 10.1007/s12017-013-8260-z
20. Zhang S, Jiang C, Liu H, Guan Z, Zeng Q, Zhang C, et al. Fluoride-elicted developmental testicular toxicity in rats: roles of endoplasmic reticulum stress and inflammatory response. Toxicol Appl Pharmacol. (2013) 271:206–15. doi: 10.1016/j.taap.2013.04.033
21. Sholl LM, Asner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thor Oncol. (2015) 10:768–77. doi: 10.1097/TO.0000000000000156
22. Gonzalez-Vallinas M, Rodriguez-Paredes M, Albrecht M, Sticht C, Stichel D, Gutekunst J, et al. Epigenetically regulated chromosome 14q32 miRNA cluster induces metastasis and predicts poor prognosis in lung adenocarcinoma patients. Mol Cancer Res. (2018) 16:390–402. doi: 10.1158/1541-7786.MCR-17-0334
23. Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z. Gefinitin as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. (2007) 57:359–64. doi: 10.1016/j.lungcan.2007.03.011
24. Hwang SJ, Lee HW, Kim HR, Song HJ, Lee DH, Lee H, et al. Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1. Oncotarget. (2015) 6:20434–48. doi: 10.18632/oncotarget.3886
25. Yu W, Peng W, Jiang H, Sha H, Li J. LncRNA HOXA11-AS promotes proliferation and invasion by targeting miR-124 in human non-small cell lung cancer cells. Tumour Biol. (2017) 39:101428317721440. doi: 10.17775/tumour.2017.39.001.001
26. Zhang L, Zhang QF, Pan GF, Zhao JP. Enhanced expression of long non-coding RNA ZFXF1 promotes the invasion and metastasis in lung adenocarcinoma. Biomed Pharmacother. (2014) 68:401–7. doi: 10.1016/j.biopha.2014.03.001
27. Wang W, Lai LC, Tsai MH, Liu TP, Chuang EY. Survival prediction model with long non-coding RNA profile in lung adenocarcinoma cancer. Cancer Res. (2015) 75(15 Suppl):170. doi: 10.1158/1538-7445.AM2015-170
28. Candelaria PV, Rampoldi A, Harbuzariu A, Gonzalez-Perez RR. Leptin signaling and cancer chemoresistance: perspectives. World J Clin Oncol. (2017) 8:106–19. doi: 10.5306/wjco.v8.i8.106
29. Pathak RR, Grover A, Malaney P, Quarni W, Pandit A, Allen-Gipson D, et al. Loss of phosphatase and tensin homolog (PTEN) induces leptin-mediated leptin gene expression: feed-forward loop operating in the lung. J Biol Chem. (2013) 288:29821–35. doi: 10.1074/jbc.M113.481523
30. Zheng XI, Yang ZY, Dong YJ, Zhang GY, Sun MF, An XK, et al. Downregulation of leptin inhibits growth and induces apoptosis of lung cancer cells via the Notch and JAK/STAT3 signaling pathways. Biol Open. (2016) 5:794–800. doi: 10.1242/bio.017798

SUPPLEMENTARY MATERIAL

This Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.01344/full#supplementary-material
33. Weng Y, Fan X, Bai Y, Wang S, Huang H, Yang H, et al. SLC2A5 promotes lung adenocarcinoma cell growth and metastasis by enhancing fructose utilization. *Cell Death Discov.* (2018) 4:38. doi: 10.1038/s41420-018-0038-5

34. You J, Wang L, Huang J, Jiang M, Chen Q, Wang Y, et al. Low glucose transporter SLC2A5-inhibited human normal adjacent lung adenocarcinoma cytoplasmic pro-B cell development mechanism network. *Mol Cell Biochem.* (2015) 399:71–6. doi: 10.1007/s11010-014-2233-x

35. Chen WL, Wang YY, Zhao A, Xia L, Xie G, Su M, et al. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. *Cancer Cell.* (2016) 30:779–91. doi: 10.1016/j.ccell.2016.09.006

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Jiang, Zhao, Yang, Sun, Li and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.